David A. Spellman net worth and biography

David Spellman Biography and Net Worth

David Spellman joined Akebia in June 2020 and is Senior Vice President, Chief Financial Officer. Mr. Spellman has two decades of strategic and operational finance experience in fast growing companies within the biopharmaceutical and healthcare industries. Prior to joining Akebia, Mr. Spellman served as Chief Financial Officer and Chief Business Officer of Intarcia Therapeutics, Inc., a biopharmaceutical company, since November 2019, and as Chief Business Officer at Intarcia from June 2019 to November 2019. From March 2018 to June 2019, Mr. Spellman served as the Chief Financial Officer at Mersana Therapeutics, Inc., a clinical stage antibody drug conjugate company. Before Mersana, Mr. Spellman held various positions at Vertex Pharmaceuticals, Inc., most recently Vice President of Corporate, Commercial and International Finance. While at the company, he also supported the global pricing, reimbursement, and launches of Kalydeco® and Orkambi® and the U.S. launch of INCIVEK. Mr. Spellman spent four years at Millennium Pharmaceuticals where he held several positions in the Finance team, including operating as a member of the VELCADE® launch team. Mr. Spellman received a B.S. in economics from The Wharton School, University of Pennsylvania.

What is David A. Spellman's net worth?: The estimated net worth of David A. Spellman is at least $708,969.50 as of March 1st, 2023. Mr. Spellman owns 510,050 shares of Akebia Therapeutics stock worth more than $708,970 as of April 18th. This net worth estimate does not reflect any other investments that Mr. Spellman may own. Learn More about David A. Spellman's net worth.
How do I contact David A. Spellman?: The corporate mailing address for Mr. Spellman and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on David A. Spellman's contact information.
Has David A. Spellman been buying or selling shares of Akebia Therapeutics?: David A. Spellman has not been actively trading shares of Akebia Therapeutics during the last ninety days. Most recently, David A. Spellman sold 7,210 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $0.88, for a transaction totalling $6,344.80. Following the completion of the sale, the chief financial officer now directly owns 510,050 shares of the company's stock, valued at $448,844. Learn More on David A. Spellman's trading history.
Who are Akebia Therapeutics' active insiders?: Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.
Are insiders buying or selling shares of Akebia Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 410,124 shares worth more than $562,184.43. The most recent insider tranaction occured on February, 29th when COO Michel Dahan sold 8,661 shares worth more than $13,684.38. Insiders at Akebia Therapeutics own 3.8% of the company. Learn More about insider trades at Akebia Therapeutics.
Information on this page was last updated on 2/29/2024.

David A. Spellman Insider Trading History at Akebia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/1/2023	Sell	7,210	$0.88	$6,344.80	510,050
3/1/2022	Sell	803	$2.17	$1,742.51

David A. Spellman Buying and Selling Activity at Akebia Therapeutics

Akebia Therapeutics Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.39

$1.36

$1.42

50 Day Range

MA: $1.61

$1.35

$2.24

2 Week Range

Now: $1.39

$0.59

$2.48

Volume

2,935,203 shs

Average Volume

4,424,594 shs

Market Capitalization

$291.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…